{
  "cached_trial": {
    "deepseek-coder_direct_mcode_evidence_based_concise": {
      "rater_id": "deepseek-coder_direct_mcode_evidence_based_concise",
      "trial_id": "cached_trial",
      "mcode_elements": [
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Conditions: Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "breast cancer patient treated with adjuvant chemotherapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "367336001",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "breast cancer patient treated with adjuvant chemotherapy"
        },
        {
          "element_type": "Patient",
          "code": "424144002",
          "display": "Current chronological age (observable entity)",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "minimumAge: 18 Years"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "patients with early breast cancer"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "adjuvant chemotherapy with AC (adriamycin-cyclophosphamide) or CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "during the adjuvant chemotherapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108606009",
          "display": "Doxorubicin",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "AC (adriamycin-cyclophosphamide) or CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387460002",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "AC (adriamycin-cyclophosphamide) or CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387460002",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387460002",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "AC (adriamycin-cyclophosphamide)"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "adjuvant chemotherapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108606009",
          "display": "Doxorubicin",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "AC (adriamycin-cyclophosphamide)"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108606009",
          "display": "Doxorubicin",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "CAF (adriamycin-cyclophosphamide-5-fluorouracil)"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Adjuvant Chemotherapy for Breast Cancer Patients"
        },
        {
          "element_type": "CancerTreatment",
          "code": "367336001",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients"
        },
        {
          "element_type": "CancerTreatment",
          "code": "71388002",
          "display": "Procedure",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.8,
          "evidence_text": "Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer Female"
        },
        {
          "element_type": "PatientSex",
          "code": "248153007",
          "display": "Female",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer Female"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Invasive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ."
        },
        {
          "element_type": "CancerCondition",
          "code": "92546004",
          "display": "Ductal carcinoma in situ of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ."
        },
        {
          "element_type": "PatientDemographics",
          "code": "184099003",
          "display": "Age 18 years or older",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Age > 18 years."
        },
        {
          "element_type": "PatientDemographics",
          "code": "248152002",
          "display": "Female",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Female gender."
        },
        {
          "element_type": "CancerTreatment",
          "code": "367336001",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients who have received neoadjuvant chemotherapy for their current diagnosis."
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "to in aid removal of breast cancers"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "breast cancer locator (BCL) surgical device to in aid removal of breast cancers"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "breast cancers"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2 positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "HER2-positive Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Male breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Male Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Stage IV Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2 positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients with HER-2+ Stage IV breast cancer that have been maximally treated and not in a complete remission"
        },
        {
          "element_type": "TNMStage",
          "code": "399537006",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients with HER-2+ Stage IV breast cancer that have been maximally treated and not in a complete remission"
        },
        {
          "element_type": "PatientDemographics",
          "code": "424144002",
          "display": "Age 18 years or older",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Subjects must be > 18 years old"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387018007",
          "display": "Trastuzumab therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates"
        },
        {
          "element_type": "CancerTreatment",
          "code": "373871005",
          "display": "Hormonal therapy for cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387132000",
          "display": "Bisphosphonate therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates"
        },
        {
          "element_type": "CancerCondition",
          "code": "94260004",
          "display": "Brain metastasis",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Active brain metastasis"
        },
        {
          "element_type": "CancerCondition",
          "code": "128348002",
          "display": "Skeletal metastasis",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Skeletal or bone-only disease that is measurable by FDG PET imaging will also be allowed"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2-positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "patients with HER2-positive stage IV breast cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "315025001",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "patients with HER2-positive stage IV breast cancer"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608007",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Drugs used in chemotherapy, such as cyclophosphamide"
        },
        {
          "element_type": "CancerTreatment",
          "code": "763703003",
          "display": "T-cell immunotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "ex vivo-expanded HER2-specific T cells"
        },
        {
          "element_type": "CancerTreatment",
          "code": "418992000",
          "display": "Cancer vaccine therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "Vaccines made from HER2 peptides may help the body build an effective immune response"
        },
        {
          "element_type": "CancerTreatment",
          "code": "418992000",
          "display": "Cancer vaccine therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608007",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients receive cyclophosphamide IV on day -1"
        },
        {
          "element_type": "CancerTreatment",
          "code": "763703003",
          "display": "T-cell immunotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2-positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "HER2-Positive Stage IV Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2-positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "HER-2-Positive Breast Cancer"
        },
        {
          "element_type": "TNMStage",
          "code": "444256004",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Stage IV Breast Cancer"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108290001",
          "display": "Adoptive T-cell therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387317001",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Cyclophosphamide After Vaccine Therapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "418992009",
          "display": "Peptide vaccine therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Peptide Vaccine in Patients With Advanced Stage HER-2-Positive Breast Cancer"
        }
      ],
      "success": true,
      "error_message": "",
      "execution_time_seconds": 0.0,
      "timestamp": "2025-09-20T00:28:15.323259"
    },
    "deepseek-chat_direct_mcode_evidence_based_concise": {
      "rater_id": "deepseek-chat_direct_mcode_evidence_based_concise",
      "trial_id": "cached_trial",
      "mcode_elements": [
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer Female"
        },
        {
          "element_type": "PatientSex",
          "code": "248153007",
          "display": "Female",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer Female"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Invasive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ."
        },
        {
          "element_type": "CancerCondition",
          "code": "92546004",
          "display": "Ductal carcinoma in situ of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ."
        },
        {
          "element_type": "PatientDemographics",
          "code": "248152002",
          "display": "Female",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Female gender."
        },
        {
          "element_type": "PatientDemographics",
          "code": "424144002",
          "display": "Age greater than 18 years",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Age > 18 years."
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "to create a breast cancer locator (BCL) surgical device to in aid removal of breast cancers"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Conditions: Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "breast cancer patient treated with adjuvant chemotherapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "367336001",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "breast cancer patient treated with adjuvant chemotherapy"
        },
        {
          "element_type": "PatientDemographics",
          "code": "424144002",
          "display": "Current chronological age",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "minimumAge: 18 Years"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "patients with early breast cancer"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "adjuvant chemotherapy with AC (adriamycin-cyclophosphamide) or CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "during the adjuvant chemotherapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108725007",
          "display": "Doxorubicin",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "AC (adriamycin-cyclophosphamide) or CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387317007",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "AC (adriamycin-cyclophosphamide) or CAF (adriamycin-cyclophosphamide-5-fluorouracil) combinations"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "adjuvant chemotherapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608008",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "adjuvant chemotherapy"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"
        },
        {
          "element_type": "CancerTreatment",
          "code": "367336001",
          "display": "Chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108290001",
          "display": "Adjuvant chemotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"
        },
        {
          "element_type": "AdverseEvent",
          "code": "267432007",
          "display": "Leucopenia",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Lifemel Honey to Reduce Leucopenia During Chemotherapy"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2 positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "HER2-positive Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Male breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Male Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "315025001",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Stage IV Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2 positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients with HER-2+ Stage IV breast cancer that have been maximally treated and not in a complete remission"
        },
        {
          "element_type": "TNMStage",
          "code": "444256004",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients with HER-2+ Stage IV breast cancer that have been maximally treated and not in a complete remission"
        },
        {
          "element_type": "PatientDemographics",
          "code": "424144002",
          "display": "Age greater than 18 years",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Subjects must be > 18 years old"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387607008",
          "display": "Trastuzumab therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates"
        },
        {
          "element_type": "CancerTreatment",
          "code": "373928009",
          "display": "Hormonal therapy for cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387125007",
          "display": "Bisphosphonate therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates"
        },
        {
          "element_type": "CancerCondition",
          "code": "94260004",
          "display": "Brain metastasis",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Active brain metastasis"
        },
        {
          "element_type": "CancerCondition",
          "code": "399068003",
          "display": "Bone metastasis",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Skeletal or bone-only disease that is measurable by FDG PET imaging will also be allowed"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2-positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "patients with HER2-positive stage IV breast cancer"
        },
        {
          "element_type": "TNMStage",
          "code": "444256004",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "patients with HER2-positive stage IV breast cancer"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387608007",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Drugs used in chemotherapy, such as cyclophosphamide"
        },
        {
          "element_type": "CancerTreatment",
          "code": "763703007",
          "display": "T-cell immunotherapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "ex vivo-expanded HER2-specific T cells"
        },
        {
          "element_type": "CancerTreatment",
          "code": "418992000",
          "display": "Cancer vaccine therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.9,
          "evidence_text": "Vaccines made from HER2 peptides may help the body build an effective immune response"
        },
        {
          "element_type": "CancerTreatment",
          "code": "763703007",
          "display": "Adoptive cell transfer",
          "system": "http://snomed.info/sct",
          "confidence_score": 0.8,
          "evidence_text": "adoptively transferred HER-2-specific TE cells derived from TCM or TEM precursors"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "HER2-positive breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "HER2-Positive Stage IV Breast Cancer"
        },
        {
          "element_type": "TNMStage",
          "code": "444256004",
          "display": "Stage IV breast cancer",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "HER2-Positive Stage IV Breast Cancer"
        },
        {
          "element_type": "CancerTreatment",
          "code": "108290001",
          "display": "Adoptive T-cell therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes"
        },
        {
          "element_type": "CancerTreatment",
          "code": "387317001",
          "display": "Cyclophosphamide",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy"
        },
        {
          "element_type": "CancerTreatment",
          "code": "418992009",
          "display": "Vaccine therapy",
          "system": "http://snomed.info/sct",
          "confidence_score": 1.0,
          "evidence_text": "After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer"
        }
      ],
      "success": true,
      "error_message": "",
      "execution_time_seconds": 0.0,
      "timestamp": "2025-09-20T00:28:15.323517"
    },
    "deepseek-coder_direct_mcode_evidence_based": {
      "rater_id": "deepseek-coder_direct_mcode_evidence_based",
      "trial_id": "cached_trial",
      "mcode_elements": [
        {
          "element_type": "ResearchStudy",
          "code": "SINGLE_GROUP",
          "display": "Single Group Assignment",
          "system": "http://hl7.org/fhir/research-study-classification",
          "confidence_score": 1.0,
          "evidence_text": "\"interventionModel\": \"SINGLE_GROUP\""
        },
        {
          "element_type": "ResearchStudy",
          "code": "NONE",
          "display": "No Masking",
          "system": "http://hl7.org/fhir/masking-level",
          "confidence_score": 1.0,
          "evidence_text": "\"masking\": \"NONE\""
        },
        {
          "element_type": "ResearchStudy",
          "code": "OTHER",
          "display": "Other",
          "system": "http://hl7.org/fhir/research-study-prim-purpose-type",
          "confidence_score": 1.0,
          "evidence_text": "\"primaryPurpose\": \"OTHER\""
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "SNOMED CT",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Infiltrating duct carcinoma of breast",
          "system": "SNOMED CT",
          "confidence_score": 1.0,
          "evidence_text": "Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ."
        },
        {
          "element_type": "CancerCondition",
          "code": "86049000",
          "display": "Carcinoma in situ of breast",
          "system": "SNOMED CT",
          "confidence_score": 1.0,
          "evidence_text": "Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ."
        },
        {
          "element_type": "TumorSize",
          "code": "LP212175-6",
          "display": "Tumor size",
          "system": "LOINC",
          "confidence_score": 1.0,
          "evidence_text": "Tumor size at least 1 cm in diameter as visualized on mammogram or US."
        },
        {
          "element_type": "CancerRelatedMedication",
          "code": "C945",
          "display": "Neoadjuvant chemotherapy",
          "system": "NCI Thesaurus",
          "confidence_score": 1.0,
          "evidence_text": "Patients who have received neoadjuvant chemotherapy for their current diagnosis."
        },
        {
          "element_type": "ResearchStudy",
          "code": "LA33-6",
          "display": "Yes",
          "system": "LOINC",
          "confidence_score": 1.0,
          "evidence_text": "Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted."
        },
        {
          "element_type": "ResearchStudy",
          "code": "LA33-6",
          "display": "Yes",
          "system": "LOINC",
          "confidence_score": 1.0,
          "evidence_text": "A staging, pre-operative breast MRI is considered to be clinically indicated."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "The purpose of this study is to determine whether a supine breast MRI obtained with a second intravenous injection of gadolinium contrast immediately after a standard clinical prone breast MRI will provide sufficient tumor visualization to allow a Radiologist to define and outline the tumor edges (\"segment\" the tumor)."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "The clinical pre-operative breast MRI exam will be obtained in the prone position with intravenous (IV) Gadolinium (Gd) contrast injection per standard of care clinical protocol."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "After completion of the standard clinical prone breast MRI, the participant will be re-positioned and the investigative supine breast MRI protocol with a second dose of IV Gd will be obtained."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "A second dose of contrast equal to the first dose will be given, and additional images will be obtained in the supine position."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "Subtraction images will be generated for both the prone and the supine sequences."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "It is hypothesized that the second contrast injection will generate tumor-to-fibroglandular contrast differences such that supine subtraction images will allow visualization and segmentation of the tumor equal to prone segmentation images."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "It is expected that the addition of a second injection of contrast will improve the ability to visualize and accurately segment the supine post-Gd images."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "While the total dose of gadolinium delivered in two injections is twice the amount normally given during a clinical prone breast MRI, this total dose is equal to that administered for other clinical MRI studies such as cardiac MRI."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Research Study",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "No additional imaging or testing will be required for this research study following the standard clinical MRI."
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Clinical Trial",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "briefTitle: 21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial"
        },
        {
          "element_type": "ResearchStudy",
          "code": "NCT05131607",
          "display": "NCT05131607",
          "system": "http://clinicaltrials.gov",
          "confidence_score": 1.0,
          "evidence_text": "nctId: NCT05131607"
        },
        {
          "element_type": "ResearchStudy",
          "code": "randomized",
          "display": "Randomized allocation",
          "system": "http://hl7.org/fhir/research-study-classification",
          "confidence_score": 1.0,
          "evidence_text": "\"allocation\": \"RANDOMIZED\""
        },
        {
          "element_type": "ResearchStudy",
          "code": "parallel",
          "display": "Parallel assignment",
          "system": "http://hl7.org/fhir/research-study-classification",
          "confidence_score": 1.0,
          "evidence_text": "\"interventionModel\": \"PARALLEL\""
        },
        {
          "element_type": "ResearchStudy",
          "code": "prevention",
          "display": "Prevention",
          "system": "http://hl7.org/fhir/research-study-classification",
          "confidence_score": 1.0,
          "evidence_text": "\"primaryPurpose\": \"PREVENTION\""
        },
        {
          "element_type": "ResearchStudy",
          "code": "double-blind",
          "display": "Double blind",
          "system": "http://hl7.org/fhir/research-study-classification",
          "confidence_score": 1.0,
          "evidence_text": "\"masking\": \"DOUBLE\""
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "SNOMED CT",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer"
        },
        {
          "element_type": "CancerCondition",
          "code": "254837009",
          "display": "Malignant neoplasm of breast",
          "system": "SNOMED CT",
          "confidence_score": 1.0,
          "evidence_text": "breast cancer patient"
        },
        {
          "element_type": "CancerRelatedMedicationAdministration",
          "code": "367336001",
          "display": "Chemotherapy",
          "system": "SNOMED CT",
          "confidence_score": 1.0,
          "evidence_text": "treated with adjuvant chemotherapy"
        },
        {
          "element_type": "ResearchStudy",
          "code": "clinical-trial",
          "display": "Clinical trial eligibility criteria",
          "system": "mCODE",
          "confidence_score": 1.0,
          "evidence_text": "Eligibility Criteria: Inclusion Criteria:"
        },
        {
          "element_type": "ResearchStudy",
          "code": "minimum-age",
          "display": "Minimum age requirement",
          "system": "mCODE",
          "confidence_score": 1.0,
          "evidence_text": "minimumAge: 18 Years"
        },
        {
          "element_type": "ResearchStudy",
          "code": "healthy-volunteers",
          "display": "Healthy volunteers excluded",
          "system": "mCODE",
          "confidence_score": 1.0,
          "evidence_text": "healthyVolunteers: False"
        },
        {
          "element_type": "CancerCondition",
          "code": "C4872",
          "display": "Early Breast Cancer",
          "system": "NCI Thesaurus",
          "confidence_score": 1.0,
          "evidence_text": "early breast cancer"
        },
        {
          "element_type": "CancerRelatedMedication",
          "code": "C1326",
          "display": "Doxorubicin",
          "system": "NCI Thesaurus",
          "confidence_score": 1.0,
          "evidence_text": "adriamycin"
        },
        {
          "element_type": "CancerRelatedMedication",
          "code": "C405",
          "display": "Cyclophosphamide",
          "system": "NCI Thesaurus",
          "confidence_score": 1.0,
          "evidence_text": "cyclophosphamide"
        },
        {
          "element_type": "CancerRelatedMedication",
          "code": "C509",
          "display": "Fluorouracil",
          "system": "NCI Thesaurus",
          "confidence_score": 1.0,
          "evidence_text": "5- fluorouracil"
        },
        {
          "element_type": "CancerRelatedMedication",
          "code": "C945",
          "display": "Honey",
          "system": "NCI Thesaurus",
          "confidence_score": 1.0,
          "evidence_text": "Lifemel honey or regular honey"
        },
        {
          "element_type": "ResearchStudy",
          "code": "LA29458-3",
          "display": "Double-blind study",
          "system": "LOINC",
          "confidence_score": 1.0,
          "evidence_text": "double blind"
        },
        {
          "element_type": "LaboratoryResult",
          "code": "26464-8",
          "display": "Leukocytes [#/volume] in Blood",
          "system": "LOINC",
          "confidence_score": 1.0,
          "evidence_text": "WBC count"
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Clinical Trial",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "briefTitle: Lifemel Honey to Reduce Leucopenia During Chemotherapy"
        },
        {
          "element_type": "ResearchStudy",
          "code": "research-study",
          "display": "Clinical Trial",
          "system": "http://hl7.org/fhir/resource-types",
          "confidence_score": 1.0,
          "evidence_text": "officialTitle: Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"
        },
        {
          "element_type": "ResearchStudy",
          "code": "NCT00243165",
          "display": "Clinical Trial Identifier",
          "system": "http://clinicaltrials.gov",
          "confidence_score": 1.0,
          "evidence_text": "nctId: NCT00243165"
        },
        {
          "element_type": "CancerCondition",
          "code": "C4878",
          "display": "Breast Cancer",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "Breast Cancer Patients"
        },
        {
          "element_type": "CancerRelatedMedicationAdministration",
          "code": "C945",
          "display": "Chemotherapy",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "Chemotherapy"
        },
        {
          "element_type": "CancerRelatedMedicationAdministration",
          "code": "C15262",
          "display": "Adjuvant Chemotherapy",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "Adjuvant Chemotherapy"
        },
        {
          "element_type": "CancerRelatedMedicationAdministration",
          "code": "C15262",
          "display": "Adjuvant Chemotherapy",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "During Adjuvant Chemotherapy"
        },
        {
          "element_type": "AdverseEvent",
          "code": "C3163",
          "display": "Leucopenia",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "Leucopenia"
        },
        {
          "element_type": "AdverseEvent",
          "code": "C3163",
          "display": "Leucopenia",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "to Reduce Leucopenia"
        },
        {
          "element_type": "AdverseEvent",
          "code": "C3163",
          "display": "Leucopenia",
          "system": "http://ncimeta.nci.nih.gov",
          "confidence_score": 1.0,
          "evidence_text": "to Prevent Leucopenia"
        }
      ],
      "success": true,
      "error_message": "",
      "execution_time_seconds": 0.0,
      "timestamp": "2025-09-20T00:28:15.323748"
    }
  }
}